Dong-A ST (President/CEO Jae-Hun Jung, KRX:170900) announced on October 18th that its biosimilar IMULDOSA® (active ingredient: ustekinumab, development code DMB-3115), referencing Stelara®, has ...

Accord Healthcare Limited (Accord) announces that the Committee for Medicinal Products for Human Use (CHMP) of the European ...

Imuldosa®, a biosimilar to Stelara®, has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), paving the way for its authorization in Europe. Developed by Accord ...

The FDA has approved Imuldosa, a biosimilar to Stelara (ustekinumab), for the treatment of various chronic inflammatory diseases.

Number 5: The FDA has approved Imuldosa (ustekinumab-srlf), a biosimilar referencing Stelara (ustekinumab), for the treatment of autoimmune diseases such as plaque psoriasis, psoriatic arthritis, ...

The Food and Drug Administration (FDA) has approved Imuldosa ™ (ustekinumab-srlf), a biosimilar to Stelara ® (ustekinumab), for the treatment of various chronic inflammatory diseases. Imuldosa, ...

Biosimilars are safe, effective, and well-tolerated for psoriasis treatment, providing significant cost savings for the ...

Adalimumab biosimilar market shares have steadily increased, but challenges remain due to pricing strategies and limited government support, according to the Samsung Bioepis report.

The drug is approved for multiple inflammatory conditions and is expected to launch in the first half of 2025.

Imuldosa is used for the treatment of patients with autoimmune diseases such as plaque psoriasis, psoriatic arthritis, ...